1768. Efficacy and Safety of Switching From Boosted-Protease Inhibitors (bPI) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Regimens to the Once Daily (QD), Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-Infected Adults: Week 96 Results of the Phase 3, Randomized, Non-Inferiority EMERALD Trial

BACKGROUND: The QD STR D/C/F/TAF 800/150/200/10 mg was noninferior to bPI + F/TDF at 48 weeks in EMERALD. Efficacy and safety of D/C/F/TAF through week 96 are presented. METHODS: EMERALD (NCT02269917) is a randomized, active-controlled, open-label, international, multicenter noninferiority trial. Vi...

Descripción completa

Detalles Bibliográficos

Autores principales:	Eron, Joseph, Orkin, Chloe, Cunningham, Douglas, Pulido, Federcio, Post, Frank, De Wit, Stéphane, Lathouwers, Erkki, Hufkens, Veerle, Petrovic, Romana, Landuyt, Erika Van
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252401/ http://dx.doi.org/10.1093/ofid/ofy209.153